BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension

By afschroeder • August 30, 2025

Sahay S, Palevsky H, El-Kersh K, Restrepo-Jaramillo R, Bajwa AA, Desai S, Joly JM, Spikes LA, Eggert MS, Johri S, Shapiro SM, Fisher MR, Shah TG, Ramani GV, Mehta JP, Thrasher CM, Deng C, Smith P, Broderick M, Burger CD. BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension. Respir Med. 2025 Aug 27;248:108318. doi: 10.1016/j.rmed.2025.108318. Epub ahead of print. PMID: 40882760.

Tags: Cardiology/Epi, Dry powder inhaler, exercise capacity, Prostacyclin dosing, Publications, pulmonary arterial hypertension, Treprostinil, Veterans Administration

Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study

Murthy V, Kimura K, Theus L, Nguyen A, Grogan TR, Lokre O, Perk T, Rettig MB, Drakaki A, Shen J, Thin P, Nguyen K, Lira[...]

New strategies for valve replacement and interventional options in adults with congenital heart disease: new insights from Euro-ACHD 2025

Butera G, Chessa M, Gaio G, Kempny A, Uebing A, Michielon G, Aboulhosn J, Giamberti A, Hoschtitzky A, d'Udekem Y. New strategies for valve replacement[...]

Navigating the Complexities of Carcinoid Heart Disease and Severe Coronary Artery Disease: A Case for Multidisciplinary Collaboration

Arbit B. Navigating the Complexities of Carcinoid Heart Disease and Severe Coronary Artery Disease: A Case for Multidisciplinary Collaboration. Cureus. 2025 Dec 23;17(12):e99940. doi: 10.7759/cureus.99940.[...]